Anti-VEGF monoclonal antibody
|
Indications for use
|
Bevacizumab |
Metastatic colorectal cancer |
Non-small-cell lung cancer |
Glioblastoma multiforme |
Metastatic renal cell cancer |
Macular degeneration |
Metastatic HER2 negative breast cancer |
Persistent, recurrent, and metastatic cervical cancer |
Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer |
|
VEGF decoy receptor (VEGF-Trap)
|
Indications for use
|
Aflibercept |
Metastatic colorectal cancer |
|
Tyrosine kinase inhibitors
|
Indications for use
|
Sorafenib |
Metastatic renal cell cancer |
Hepatic cancer (hepatocellular carcinoma) |
Sunitinib |
Metastatic renal cell carcinoma |
Gastrointestinal stromal tumour |
Pancreatic neuroendocrine tumour |
Cabozantinib |
Medullary thyroid cancer |
Erlotinib |
Non-small-cell lung cancer |
Pancreatic cancer |
Axitinib |
Metastatic renal cell cancer |
Pegaptanib |
Macular degeneration |
Ranibizumab |
Macular degeneration |
Pazopanib |
Metastatic renal cell cancer |
Soft tissue sarcoma |
Vandetanib |
Medullary thyroid cancer |
Regorafenib |
Metastatic colorectal cancer |
Gastrointestinal stromal tumour |
Imatinib |
Chronic myeloid leukemia |
Renal cell cancer |
Gastrointestinal stromal tumour |
Dasatinib |
Philadelphia chromosome-positive (Ph+) chronic |
myeloid leukemia (CML) |
Chronic phase Ph+ CML |
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (Ph+ ALL) |
|
Mammalian target of rapamycin inhibitors (mTOR inhibitors)
|
Indications for use
|
Temsirolimus |
Renal cell cancer |
Everolimus |
Advanced breast cancer |
Advanced renal cell cancer |
Pancreatic neuroendocrine tumour |
Tuberous sclerosis complex |
Subependymal giant cell astrocytoma |